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Nerve Growth Factor (NGF) was initially studied for its role as a key player in the regulation of peripheral innervations. However,
the successive ﬁnding of its release in the bloodstream of male mice following aggressive encounters and its presence in the central
nervoussystemledtothehypothesisthatvariationsinbrainNGFlevels,causedbypsychosocialstressor,andtherelatedalterations
inemotionality,couldbefunctionaltothedevelopmentofproperstrategiestocopewiththestressoritselfandthustosurvive.Years
later this vision is still relevant, and the body of evidence on the role of NGF has been strengthened and expanded from trophic
factor playing a role in brain growth and diﬀerentiation to a much more complex messenger, involved in psychoneuroendocrine
plasticity.
1.Introduction
At the beginning of the 1950s, the Nobel Laureate Rita Levi-
Montalcini discovered and characterized the Nerve Growth
Factor (NGF) as a key player in target-mediated regulation
of peripheral innervations [1, 2]. The pioneer studies
performed by her and Victor Hamburger ﬁrst showed that
the nervous system requires an adequate supply of trophic
factors (neurotrophins—NTs) from the environment for
survival and development. In addition, and most intrigu-
ingly, these studies ﬁrst raised the concept of cell death
playing a pivotal role in this speciﬁc context. In particular,
target tissues might determine the size and morphology
of the peripheral innervations by regulating cell death
among neurons and by making the NTs available only
in limited amounts, ﬁnally resulting in the selection only
of those neurons which have established the quantitative
and qualitative numbers of connections (with the target
tissue). Subsequent studies have demonstrated that, during
nervous system development, NGF is released by the target
tissue, taken up in responsive neurons by receptor-mediated
endocytosis and transported retrogradely to the cell body
where it exerts its trophic/diﬀerentiative eﬀects through its
low (p75NTR) and high aﬃnity receptors (TrkA) [3–7].
In particular, while the p75NTR can cause apoptosis in
a variety of systems, when coexpressed with TrkA, it can
modify their ligand-binding activity, dose-responsiveness,
and kinase activity, leading to increased survival, neurite
outgrowth, and synaptic plasticity [8–12].
Since these ﬁrst investigations on target-controlled neu-
ronal survival, NGF has been one of the most thoroughly
studied NTs, regulating the survival, development, and
trophism of speciﬁc neuronal populations in the peripheral
and central nervous system (CNS) [13]. While in the
periphery this NT was ﬁrst recognized for its action on
the sympathetic ganglia, in the adult brain the highest
levels of NGF are found in hippocampus, cortex, and
olfactory regions, which represent targets for basal forebrain
cholinergic neurons [14, 15]. NGF acts as a trophic factor
for these neurons since its administration in vivo increases
the levels of choline acetyltransferase [16, 17] while rescuing
from death basal forebrain neurons following transection
of the septo-hippocampal pathways [18]. In addition to the
nervous system, NTs exert their eﬀects on various other
tissue compartments [19–26]. The largest amount of NGF
is produced in the salivary glands of adult male mice, which
are the largest and best available source of this NT (smaller
concentrations of this NT can be found in snake venom,
guinea pig prostate, the seminal ﬂuid of guinea pigs and
bulls, in the human skin, and in numerous tissues and body2 Neural Plasticity
ﬂuids [13]). Furthermore, a number of other cells outside
the nervous system, including epithelial cells, ﬁbroblasts,
lymphocytes, and activated macrophages, synthesize NGF
[27–29].
Since NGF discovery, no explanation was available for
almost three decades on NGF physiological role in adult ani-
mals. Most neurobiologists, for a very long time, explained
its presence in adult animals because of its ancestral physio-
logical role during ontogeny. NGF was originally described
as a protein exclusively acting on sympathetic peripheral
neuronsandonlymuchlaterit wasfoundtobealsoactiveon
central nervous system neurons and on a variety of immune
cell types [30]. Overall, the presence of NGF in those
limbic areas of the CNS involved in mood and cognition
and in the orchestration of neuroendocrine responses and
circadian activities, as well as in cells of the immune and
endocrine system, indicates a much wider role for this NT
than previously hypothesized and suggests that it might
function as intercellular messenger or even a humoral factor
to help regulate endocrine responses to stress [19, 31–35].
2. Stress Renewed CNS andAdrenal Plasticity
Stressmaybedeﬁnedasanychangeoftheinternalorexternal
milieu perturbing the maintenance of homeostasis of an
organism. In complex organisms, stress responses involve
a coordinated set of intercellular signals eventually result-
ing in the removal of the organism from, or adaptation
to, the stressful situation. Coping strategies are therefore
important components of the stress response allowing an
animal to “fright, ﬁght or ﬂight” [36]. Pivotal to these
allostatic/adaptive responses is the neuroendocrine system
thatemploysneuropeptidesandhormonesasmediators.The
hypothalamic-pituitary-adrenal (HPA) axis (which releases
the glucocorticoids—GCs—hormones) and sympathetic
adrenomedullary systems (which releases catecholamines)
coordinate the stress response. Although the cascade of
responses to acute stressful events originates at the CNS
level, peripheral structures, such as the adrenal glands, act
in interplay and feedback on the brain to maintain body
homeostasis[37,38].Bycontrast,chronicstresscanpromote
and exacerbate pathophysiological conditions through these
same systems, leading to allostatic overload [39]. The
adaptive plasticity of chronic stress involves many mediators,
includingGCs,excitatoryaminoacids,andNTs,suchasNGF
and also Brain-Derived Neurotrophic Factor (BDNF). These
latter can participate in the HPA axis response to stressful
stimuli at diﬀerent anatomical levels [38, 40].
In the wild, adult male mice exhibit high levels of in-
traspeciﬁc aggressive behavior towards conspeciﬁcs mainly
related to territorial defense. In the laboratory setting, the
agonistic behavior of male mice can be elicited after 4–6
weeks of social isolation and represents a psychosocial stress-
ful condition that has been shown to markedly alter NGF
and BDNF levels both in plasma as well as in selected brain
areas, including the hypothalamus and hippocampus [41,
42]. In the mouse, NGF is mainly synthesized and released
from the submaxillary salivary glands [5, 43]. Neurobe-
havioral studies demonstrated that both male intraspeciﬁc
ﬁghting and lactating females nest-defense, raised against a
potentially infanticidal conspeciﬁc male, induce a massive
release of NGF from salivary glands into the bloodstream
of adults. In particular, circulating levels of NGF are highly
correlated with the number of ﬁghting episodes and most
intriguingly to the social status achieved in ﬁghting mice.
Thus, subjects experiencing repeated defeat and submissions
(i.e., a subordinate status) were characterized by a two-time
increase in the amount of circulating NGF compared to
attacking mice that achieved a dominant status [44, 45]. In
this speciﬁc context it is worth to note that physical stressors,
such as cold water, foot shocks, or restraint stress exposure,
exert a minor eﬀect on NGF release [43, 46].
Following ﬁghting behavior, adrenal weight increases
quite markedly and quickly in male mice suggesting that
social/aggressive behavior might control circulating NGF
release from salivary glands and that these might in turn
control adrenal morphology as well as adrenal functional
status [47, 48]. This hypothesis has been supported by data
showing that exogenous NGF administration (i.p. delivery,
for 10 consecutive days in order to mimic 10 subsequent
daily ﬁghting sessions) results in a marked adrenal gland
hypertrophy [43, 47, 48]. Thus, NGF release may exert
an inhibitory feedback eﬀect on aggressive behavior. The
higher NGF release and the hypertrophy of the adrenals,
occurring in subordinates male mice, suggest a “regulative
loop” involving NGF-mediated increase of glucocorticoids
secretion (upon adrenals) acting to enhance a submissive
proﬁle (Figure 1)[ 46, 47, 49].
Further experimental evidence supports the idea that
NGF expression may be regulated by behavioral activation.
In particular, intermale aggressive behavior induces a large
increase in NGF mRNA and protein in hypothalamus,
especiallyintheparaventricularnucleus,withnomeasurable
changes in cerebral cortex, hippocampus, and cerebellum
[50]. The increase in hypothalamic NGF following intermale
aggressive behavior is not abolished by sialoadenectomy,
suggesting that hypothalamic NGF is not of salivary origin
[43]. Alleva and Aloe hypothesized that the rather rapid
increase in levels of brain NGF, which follows a psychosocial
stressful event, could allow some renewal of brain plasticity
at adulthood [46].
Indeed,NGFcouldcontributetostructuralchanges,such
as the formation of dendritic spines or collateral sprouting,
ultimately altering the structure of neural connections in the
mature brain [46, 47]. Another possibility is that hypothala-
mic NGF might aﬀect levels of other peptides or hormones
present in the hypothalamus [51–55]. Taken together, these
studies suggest that hypothalamic NGF levels are responsive
to (and modiﬁed by) stimuli of a psychological nature, most
likely associated with anxiety and fear. As hypothalamus is
involved in the maintenance of physiological homeostasis, it
is likely that hypothalamic NGF aﬀects, or cooperates with,
hormones and/or neurotransmitters present in this brain
area to ultimately integrate behavioral and neuroendocrine
responses [31, 46].
In this complex scenario, peripheral organs, such as
adrenal glands, might be seen as remote CNS stations










Figure 1: NGF secretion may exert an inhibitory feedback eﬀect
on the aggressive behavior of male mice. The higher NGF release
andthehypertrophyoftheadrenals,occurringinsubordinatesmale
mice, suggest a “regulative loop” involving NGF-mediated increase
of glucocorticoids secretion (upon adrenals) acting to enhance a
submissive proﬁle.
peripheral”locationprovidesmostofthebodywitharemote
station, in strict hormonal connection with some func-
tionally integrated brain zones, to easily and eﬃcaciously
control the entire organisms. In addition and more impor-
tantly, these glands are morphologically (and functionally)
endowed with a very high degree of plasticity leading to
profound endocrine and behavioral modiﬁcations, and both
short-term changes in behavioral reactivity at the individual
level and changes in mouse population structure (e.g., major
behavioral changes in reactivity to social stimulation) could
be expected [43, 56–59]. Thus, NGF appears to play a role
in stress-mediated changes in behavioral responses, leading
to imprinting-like phenomena at adulthood, in which such
social stimuli suddenly become relevant and produced long-
lasting behavioral alterations. In particular, it could be
hypothesized that variations in the hypothalamic NGF,
caused by psychosocial stressor, and the related alterations
in emotionality, could be functional to the development of
proper strategies to cope with the stressor itself and thus to
survive. NGF could shift some still unknown brain zones
backwards to an “immature-like” stage [46, 49].
3 .T h eR o l eo fN G Fa tt h eP e ri p h e ra lL ev el
Belonging to the neuroendocrine system, the anterior pitu-
itary gland represents an important relay station between the
periphery and the CNS under the control of hypothalamic
hormones and peripheral signals. The integration operated
by this gland determines the extent of hormonal secretion
in diﬀerent physiological situation and NGF and BDNF
appear to play a neurotrophic role on the pituitary and
stimulate synthesis of neuropeptides. The ﬁrst evidence of
such a role for NTs came from studies suggesting that,
following intravenous injection, NGF increased the secretion
of adrenocorticotropic hormone (ACTH) as well as the
concentration of GCs, and that following a psychosocial
stress, a massive release of NGF occurred in the peripheral
circulation, associated with increased hypothalamic NGF
mRNA and protein levels [43, 60, 61].
NGF is synthesized in the granular convoluted tubules
within the submandibular glands soon after puberty (much
more in male than in female subjects) [5, 13]. The functional
signiﬁcance of the large amounts of NGF observed in the
mousesubmandibularglandsisnotfullyelucidated;however
it has been shown to be released into the bloodstream
as a result of intraspeciﬁc aggressive behavior acting on
nerve, chromaﬃn, mast cells, and lymphocytes [43, 61,
62]. The adrenal glands are intrinsically characterized by
a high degree of plasticity from a morphological (and
functional) point of view [43]. Their size varies according
to short- and medium-term life stressful events, and such a
morpho-functional change is mirrored by subtle and rapid
central modiﬁcation in the expression of the hippocampal
glucocorticoids receptor (GR) system, in the excitability of
hippocampal neurons, neurogenesis of the dentate gyrus,
synaptogenesis in the CA1 region, and dendritic remodeling
in the CA3 region, just to mention few [63]. NGF appears
as key player in the ontogeny of adrenal glands as its
administration induces the transformation of chromaﬃn
cells in sympathetic nerve cells in the adrenal medulla. By
contrast, injections of NGF antiserum (from prenatal day 17
to postnatal day 10 in rats) inhibit adrenal development and
diﬀerentiation through a massive destruction of chromaﬃn
cell precursors [64] overall showing the main role played by
NGF in critical developmental stages [37, 38].
Thus adrenal glands can be viewed as representing the
lastpairofvertebralganglia.Duringearly(inaltricialrodents
late-gestational) developmental stages, thanks to a complex
interaction of neurohormonal factors (including GCs and
NGF, as reported just below), they do not fully diﬀeren-
tiate as adult-like ganglia but maintain several fetal-type
characteristics. Therefore, their enhanced morphofunctional
plasticity is maintained through adulthood, rendering them
a remote (control) neurohormonal station involved in a
continuous dialog with the brain for the maintenance of
body homeostasis [37, 38].
A large body of evidence suggests a link between adrenal
size modiﬁcation and coping strategies to face stressful
events which might underlie the association often found
for a pathologic increase in corticosteroid hormones and
vulnerability to psychiatric disorders [46]. Since the adrenal
gland appears to be one of the biological targets of NGF,
one way this growth factor could exert a physiologic role is
through its action on this structure. NGF administered for
6–10 consecutive days results in a dose-dependent increase4 Neural Plasticity
in adrenal weight and volume by enlarging both the adrenal
medulla and the cortex [43, 49]. At present, it is not clear
whether adrenal cortex hypertrophy following NGF admin-
istration in adult mice is the result of a direct action of this
NT on adrenal cortex cells or whether it is mediated through
its eﬀects on ACTH release. Interestingly, it has been shown
that conditions exist in which adrenal activity is uncoupled
fromACTH,suchasduringstarvation[65],andthissuggests
a direct eﬀect of NGF on the adrenals under speciﬁc
conditions. Furthermore, in animal models characterized by
metabolic disorders involving dysregulation of the HPA axis,
suchastypeIdiabetes,corticosteronehypersecretionappears
to occur independently from a surgein ACTH levels [38,66].
NGF might also contribute as an alternative mechanism in
inducing such rapid changes in adrenal sensitivity. Changes
in adrenal hormone secretion (e.g., increased corticosterone
levels) resulting from an increase in NGF circulating levels
could exert important eﬀects on aggressive behavior: GCs
enhance aggressive behavior in a context-dependent fash-
ion, promoting social challenge-induced aggression without
increasing aggressiveness under routine conditions in rats
[67, 68]. Indeed, at present, there is no evidence of direct
NGF eﬀects on neural substrates of aggressive behavior, and
the high molecular weight of the NGF protein seems to
exclude the possibility that it could cross the blood-brain
barrier, although a possible breakage of the NGF protein into
fragments acting on the CNS can be postulated [69]. From
a clinical application point of view, it appears interesting
to point out that successful transport of biologically active
NGF across the blood-brain barrier has been achieved by
covalently linking it to an antitransferrin receptor antibody
or by ocular delivery [38, 70, 71]. Likewise, Aloe and Alleva,
working in the team of Levi-Montalcini, analyzed all the
evidences collected up to that point on the physiological
activities exerted by NGF on CNS and non-CNS neurons
[31]. In those years, starting with mast cells [72, 73],
and much later memory B lymphocytes [74], evidences
were provided for a role of NGF on psychoneuroimmune
regulation [31, 46].
4 .T h eR o l eo fN G Fa tt h eC N S
Most of the studies on NGF were originally performed by
Rita-Levi Montalcini on the sympathetic ganglia explanted
from chick embryos [5, 75], leading to an initial fascinating
but incomplete vision of NGF as a protein molecule exerting
speciﬁc—although limited—eﬀects on peripheral sympa-
thetic neurons. Further studies, carried out, rather indepen-
dently by Barde and Thoenen, and Mobley, characterized
NGFeﬀectsoncholinergicneuronsattheCNSlevel,opening
the way to several lines of research aimed at understanding
NGF physiological roles in the brain [7, 12, 76].
NGF is essential for the development and maintenance
of sensory neurons, and for the formation of central pain
circuitry, exogenous administration of this neurotrophin to
rodents resulting in the rapid onset of hyperalgesia [69].
Together with its receptors (p75 and TrkA), it plays a
criticaltrophicroleonforebraincholinergicneurons(FCNs)
that degenerate during brain aging and neurodegenerative
disorders [77, 78]. During development, both NGF and
BDNF regulate naturally occurring cell death, synaptic
connectivity, ﬁber guidance, and dendritic morphology [79].
Furthermore, they participate to brain plasticity, being
involved in activity-dependent neuronal functions [34, 79–
81]. During early postnatal development, especially during
criticalperiods,largechangesintheconnectivityandorgani-
zation of neural networks take place [82, 83]. In this period,
the developing CNS is particularly sensitive to external
stimuli, and NGF and BDNF play a key role in modulating
brain plasticity to better cope with environmental stimuli. As
an example, mice reared in a communal nest (CN, which
consists in a single nest where three mothers keep their
pups together and share care-giving behavior from birth to
weaning) are characterized by increased NGF and BDNF
levels in selected brain areas, including hippocampus and
hypothalamus, and prolonged survival of newly generated
cells in the hippocampus. These features possibly underly
the higher propensity of CN mice to interact socially
and their better social skills when compared to subjects
reared in standard laboratory conditions [84, 85]. The adult
brain still shows signiﬁcant plasticity: for example, repeated
agonistic intermale ﬁghting in aged mouse selectively aﬀects
neurotrophin production. In particular, the social stress of
being subordinate is able to increase NGF levels in the
Subventricular Zone (SVZ) and hippocampus (a brain area
involved in learning and memory processes) leading to the
hypothesis of a regulatory role of NGF in the “emotional”
status caused by psychosocial stressors and the physiological
needs of the organism to “remember” the events leading
to an appropriate coping with the stressor itself [41, 47].
Moreover, aggressive behavior can enhance the number of
Ki67-positive cells in the SVZ of aged animals. This suggests
that, in the aged mouse, ﬁghting behavior may increase neu-
rogenesis, most probably throughout proliferation and/or
diﬀerentiation of brain stem cells [86], possibly contributing
to reduce the neuronal damage and loss caused by prolonged
GC exposure as a consequence of the social stress related to
ﬁghting [87, 88]. In addition, within the brain, the major
increase in NGF following ﬁghting has been observed in
the hypothalamus a brain area involved in the activation
of certain behaviors and in physiological modiﬁcations
inducing changes in bodily homeostasis, suggesting a role for
NGF in coping and neuroendocrine mechanisms [31].
AcorrelationbetweenchangesinNGFlevelsandanxiety-
like behaviors has been observed in humans. In particular,
NGF levels were found to be increased in the blood of young
soldiers experiencing their ﬁrst parachute jump, implying
that the release of NGF in the bloodstream is triggered by
the stress of the novel and highly arousing experience [62].
The key role of NGF in anxiety conditions is also suggested
by ﬁndings demonstrating that alcohol or heroin withdrawal
in human is also associated to changes in blood NGF levels
[89].
Chronicityofstresssystemactivationleadstothesyndro-
mal state that in 1936 Selye described as the “general adap-
tation syndrome” [90]. When facing a stressful situation, all
physiological changes, related to coping strategies, lead both
to protective and damaging eﬀects on the body. In particular,Neural Plasticity 5
on a short run they are essential for adaptation, maintenance
of homeostasis, and survival (allostasis is maintaining stabil-
ity through changes). Yet, over longer time intervals, they
impose a cost (allostatic load) that can accelerate disease
processesorparticipatetopathologicalchangespossiblycon-
tributing to the development of neurodegenerative disorders
and/or to precipitate psychopathological conditions [91].
NGF, both in the bloodstream and in certain brain areas,
is diﬀerentially expressed following environmental stressors.
A large number of evidence show that chronic stress can lead
to anxiety- and depression-like behaviors and may inﬂuence
the distribution of NGF, both in animal models and in
humans [46, 92]. Reduced NGF and BDNF signaling in
the adult brain may be involved in the pathophysiology of
psychiatric disorders, such as depression [38, 81, 93–96], and
a role for NGF has been proposed in the etiopathogenesis of
schizophrenia [97].
NTs themselves do not directly aﬀect mood but rather
play an important functional role in the modulation of
networks determining how plastic changes inﬂuences mood
[94]. In fact, it has been hypothesized that, by activating NTs
systems, successful antidepressant treatments and cotreat-
ments promote activity-dependent neuronal plasticity, pos-
sibly inducing proliferative or survival eﬀects on neural stem
cells [81]. Because of the fundamental role played by these
neurotrophic factors in shaping brain function, pathological
alterations in their concentration or action early during
development could exert long-term eﬀects on synaptic
plasticity, impairing the ability of the organism to cope with
novel/stressful situations, leading to psychopathology [98].
During development, the expression of NGF and BDNF has
beenlocalizedtothehippocampusandprefrontalcortex,two
regions which are well-studied sites of both developmental
and adult synaptic plasticity and playing a key role in
psychiatric disorders [15, 99].
Stress during prenatal and early postnatal life may
result in altered brain development and lead to a persis-
tent sensitization of limbic circuits to even mild stress at
adulthood, forming the basis for a greater susceptibility for
mood and anxiety disorders (Levine, 1967 no.49; Maccari,
2003 no.117). Numerous studies performed in rodents have
indicated that NTs are sensitive to the stress of maternal
separation and to changes in the rearing conditions and that
environmental stimulation can have both short- and long-
term eﬀects on NTs levels [84, 100–107]. It is possible to
hypothesize that while milder manipulations could promote
neural plasticity, chronic stressful conditions could sensitize
limbic structures to stress, decreasing brain plasticity and
leading to higher susceptibility to psychopathology [102,
108]. As an example, in rodents, separating mother and
infant for brief periods results in increased NGF expression
in the hippocampus, cerebral cortex, and hypothalamus in
a time-dependent manner [101, 104] while longer periods
of maternal separation (24h) also result in increased rate of




have been also found in CD-1 mice [84].
Epidemiological studies indicate that anxiety and mood
disorders are characterized by sex diﬀerences in prevalence,
presentation or therapeutic outcomes. A recent study sug-
gests that epigenetic changes, presumably in the male germ
cells, might alter the exposure to the hormones that mediate
brain masculinization, providing insight into the heritabil-
ity and pathophysiology of sex-biased neurodevelopmental
disorders [110]. In addition, a very interesting work from
Cirulli and collaborators provides evidence for a speciﬁc role
of NTs in such a gender-speciﬁc vulnerability. In particular,
BDNF and NGF were identiﬁed as neuroendocrine markers
underlying diﬀerential responses to maternal deprivation in
males and females rhesus macaques. The selective changes
in BDNF levels in females suggest a possible mechanism for
the greater vulnerability to mood disorders of this gender as
reported in humans [103].
The importance of early life experiences in the etiology
of psychiatric disorders has been now recognized; however it
has been often underemphasized. Early life stressful events,
such as childhood trauma and neglect, are associated with
depression and anxiety disorders and sustained changes in
the HPA axis [111–113]. These associations strengthen the
hypothesis that environmental factors during development
could lead to long-term enduring changes in the set-point
of the neuroendocrine system physiology and emotional
behavior.
Changes in the levels of NGF in the CNS appear also to
play an important role in the context of neurodegenerative
disorders such as Alzheimer disease (AD). The disruption of
NGFgeneintransgenicmiceleadstoalethalphenotype;thus
only the study of phenotypic knockout of NGF at adulthood
is possible [114]. Transgenic mice expressing a neutralizing
anti-NGFrecombinantantibodyarecharacterizedbyanage-
dependent neurodegenerative pathology including amyloid
plaques, insoluble and hyperphosphorylated tau, and neu-
roﬁbrillary tangles in cortical and hippocampal neurons.
Furthermore, they show an extensive neuronal loss through-
out the cortex, cholinergic deﬁcit in the basal forebrain
in addition to behavioral deﬁcits, overall being strikingly
reminiscent of human AD [115]. NGF precursor (pro-NGF)
has been shown to be highly expressed in the brains of AD
patients and to be neurotoxic when bound in a heterotrimer
with the p75 and the receptor sortilin. Interestingly, sortilin
levels are increased in aged central and peripheral neurons,
possibly rendering neurons more vulnerable to the age-
related increases in pro-NGF [116]. More recently, Capsoni
and coworkers postulated that neurodegeneration occurring
in a transgenic mouse model of AD is provoked by an
imbalance of proNGF/NGF and, consequently, of TrkA/p75
signaling such that the inactivation of TrkA determines a
strong cholinergic deﬁcit and AD-like neurodegeneration
[117]. Thus, overall, the NGF/TrkA signaling pathway has
emerged as a promising therapeutic target for the AD
pathology [118].
In addition to a possible therapeutic role in the context
of neurodegenerative disorders, Chiaretti and coworkers
investigated the role of NGF in regard to severe traumatic
brain injury (TBI) in pediatric patients [119]. TBI is the
most common cause of death and acquired disability6 Neural Plasticity
among children and young adults in developed countries
and its clinical outcome depends both or the primary
cerebral lesions and or the extent of secondary brain
damage which involves neuroinﬂammatory mechanisms. It
hasbeensuggestedthatinterleukin-6mightparticipatetothe
mechanisms of recovery from TBI through the modulation
of NGF biosynthesis, elevated levels of this neurotrophin
representing a reliable marker of good prognosis, at least
in children [119]. Moreover, and more recently, the same
authors proposed that NGF might represent an eﬀective and
safe adjunct therapy in patients (children and adults) with
severe hypoxicischemic injury suggesting a neuroprotective
mechanism exerted by NGF on the residual viable neurolog-
ical pathways of these patients [120].
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